169 related articles for article (PubMed ID: 28395515)
1. Long-term safety experience with bendamustine for injection in a real-world setting.
Martin P; Barr PM; James L; Pathak A; Kahl B
Expert Opin Drug Saf; 2017 Jun; 16(6):647-650. PubMed ID: 28395515
[TBL] [Abstract][Full Text] [Related]
2. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
3. Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma.
Hoy SM
Drugs; 2012 Oct; 72(14):1929-50. PubMed ID: 22950536
[TBL] [Abstract][Full Text] [Related]
4. Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Elefante A; Czuczman MS
Am J Health Syst Pharm; 2010 May; 67(9):713-23. PubMed ID: 20410545
[TBL] [Abstract][Full Text] [Related]
5. Fatal Stevens-Johnson syndrome/toxic epidermal necrolysis induced by allopurinol-rituximab-bendamustine therapy.
Fallon MJ; Heck JN
J Oncol Pharm Pract; 2015 Oct; 21(5):388-92. PubMed ID: 25005569
[TBL] [Abstract][Full Text] [Related]
6. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
Munakata W; Tobinai K
Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial.
Ujjani C; Cheson B
Future Oncol; 2011 Jan; 7(1):9-14. PubMed ID: 21174533
[TBL] [Abstract][Full Text] [Related]
8. Bendamustine's emerging role in the management of lymphoid malignancies.
Rummel MJ; Gregory SA
Semin Hematol; 2011 Apr; 48 Suppl 1():S24-36. PubMed ID: 21530769
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, single-arm, Phase II clinical trial of bendamustine monotherapy in patients with chronic lymphocytic leukemia in Japan.
Ogawa Y; Izutsu K; Kiguchi T; Choi I; Takatsuka Y; Ando K; Suzumiya J;
Int J Hematol; 2017 May; 105(5):631-637. PubMed ID: 28160213
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?
Gordon MJ; Lewis LD; Brown JR; Danilov AV
Expert Rev Hematol; 2017 Aug; 10(8):707-718. PubMed ID: 28664772
[TBL] [Abstract][Full Text] [Related]
11. BENDAMUSTINE: AN OLD DRUG IN THE NEW ERA FOR PATIENTS WITH NON-HODGKIN LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA.
Bogeljić Patekar M; Milunović V; Mišura Jakobac K; Perica D; Mandac Rogulj I; Kursar M; Planinc-Peraica A; Ostojić Kolonić S
Acta Clin Croat; 2018 Sep; 57(3):542-553. PubMed ID: 31168188
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
Sanchez-Gonzalez B; Peñalver FJ; Medina A; Guillén H; Calleja M; Gironella M; Arranz R; Sebastian E; de Oña R; Cánovas A; de la Fuente I; Grande C; Sancho JM; Perez R; Domingo E; Lopez-Lorenzo JL; Prieto E; Panizo C; Gorosquieta A; Perez I; Cervera JM; Marin M; Mencha C; Ramila E; Salar A
Leuk Res; 2012 Jun; 36(6):709-14. PubMed ID: 22154023
[TBL] [Abstract][Full Text] [Related]
13. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.
Saito H; Maruyama D; Maeshima AM; Makita S; Kitahara H; Miyamoto K; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Taniguchi H; Tobinai K
Blood Cancer J; 2015 Oct; 5(10):e362. PubMed ID: 26495859
[No Abstract] [Full Text] [Related]
14. Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
Martin P; Chen Z; Cheson BD; Robinson KS; Williams M; Rajguru SA; Friedberg JW; van der Jagt RH; LaCasce AS; Joyce R; Ganjoo KN; Bartlett NL; Lemieux B; VanderWalde A; Herst J; Szer J; Bar MH; Cabanillas F; Dodds AJ; Montgomery PG; Pressnail B; Ellis T; Smith MR; Leonard JP
Br J Haematol; 2017 Jul; 178(2):250-256. PubMed ID: 28419413
[TBL] [Abstract][Full Text] [Related]
15. Extended Follow-up of Patients Treated With Bendamustine for Lymphoid Malignancies.
Penne M; Sarraf Yazdy M; Nair KS; Cheson BD
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):637-644. PubMed ID: 28797620
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.
Zinzani PL; Vitolo U; Viviani S; Corradini P; Motta G; Tani M; Cascavilla N; Hohaus S; Merli F; Argnani L; Broccoli A
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):404-8. PubMed ID: 25840816
[TBL] [Abstract][Full Text] [Related]
17. Post-marketing risk analysis of bendamustine: a real-world approach based on the FAERS database.
Li D; Zhang Y; Ni JQ; Zhu J; Lu WT; Chen YL; Cheng L; Wang YQ; Li QJ; Wang J; Lu YB; Chen J; Chen L
Front Pharmacol; 2024; 15():1372401. PubMed ID: 38803441
[No Abstract] [Full Text] [Related]
18. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
Awan FT; Gore L; Gao L; Sharma J; Lager J; Costa LJ
Br J Haematol; 2016 Oct; 175(1):55-65. PubMed ID: 27293194
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Bendamustine Monotherapy in the First-Line Treatment of Patients with Chronic Lymphocytic Leukemia: Polish Lymphoma Research Group Real-Life Analysis.
Wołowiec D; Szymczyk A; Potoczek S; Krochmalczyk D; Zawirska D; Piotrowska M; Malenda A; Soroka-Wojtaszko M; Kopacz A; Wąsik-Szczepanek E; Graboś-Michalak J; Raźny M; Wichary R; Bramowicz-Jarosz B; Seweryn M; Długosz-Danecka M; Hus I
Chemotherapy; 2019; 64(3):155-162. PubMed ID: 31715597
[TBL] [Abstract][Full Text] [Related]
20. The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis.
Nordstrom BL; Knopf KB; Teltsch DY; Engle R; Beygi H; Sterchele JA
Leuk Lymphoma; 2014 Jun; 55(6):1266-73. PubMed ID: 23987821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]